Quantcast

US Drug Watchdog Expands Their Transvaginal Mesh Initiative to Younger Women Recipients & They are Offering the Names of the Best Women Attorneys For Victims

October 13, 2012

The US Drug Watchdog is expanding their initiative focused on helping women recipients of a failed transvaginal mesh, also known as a sling to women in their 20′s, 30′s, and early 40′s. The group says, “Based on the calls we are receiving at least half of the transvaginal mesh failure victims we are talking to are in their mid to late 30′s. This literally is the absolute worst medical device failure we have ever heard of because the complications are so severe. We are super passionate about making certain these victims get to the highest caliber attorneys-who are all women.” Transvaginal mesh failure occurs when the mesh fails to bind to a woman’s pelvic tissues. As a consequence of this, the body rejects the mesh that has been sewn into it. As a result, the transvaginal mesh may start to poke its way through the vaginal wall and protrude out of the vaginal tissue. This complication is more commonly referred to as “erosion.” The US Drug Watchdog is urging any woman, who has had the transvaginal mesh surgical procedure done, and now has developed severe complications to call them immediately at 866-714-6466. As part of their initiative the US Drug Watchdog is offering to send all US women, who are victims of a transvaginal mesh failure to national caliber attorneys-who are all women. http://USDrugWatchdog.Com

(PRWEB) October 11, 2012

The US Drug Watchdog is now expanding their national initiative designed to help women recipients of transvaginal mesh, that is also called a sling, who are now severely damaged by this type of medical product to younger women. Supposedly transvaginal mesh products were designed for women, who were suffering from pelvic organ prolapse, and or stress urinary incontinence. According to court records the procedure to install a transvaginal was supposed to be minimally-invasive. The US Drug Watchdog now says, “The FDA is now saying transvaginal mesh failures is causing complications in patients such as erosion and infection. Women who experience transvaginal mesh failure may need to have numerous corrective surgeries, IV therapy, blood transfusions and drainage of hematomas or abscesses.” The US Drug Watchdog is offering to help all US women, who are now victim’s of a transvaginal mesh failure get to the best possible attorneys, and the group is promising the attorneys will all be women. No other Group is offering a service like this. For more information victims of the Transvaginal Mesh Disaster are urged to contact the US Drug Watchdog anytime at 866-714-6466. http://USDrugWatchdog.Com

The US Drug Watchdog is indicating symptoms of a transvaginal mesh or sling implant failure may include:

  • Pain during sexual intercourse caused by erosion.
  • Mesh erosion through the vagina (the mesh is actually protruding out of the vaginal wall)
  • Vaginal Bleeding
  • Vaginal Infection
  • Urinary problems
  • Organ perforation

The US Drug Watchdog says, “One of the biggest problems we have with respect to our failed medical device or recalled drug initiative work is the average US consumer never hears about a drug recall or failures involving medical devices like a transvaginal mesh failure. If you have a friend, or loved one who is a recipient of a transvaginal mesh that has already failed or is showing symptoms of a failure, please have them call us at 866-714-6466. We want to make certain these transvaginal mesh failure victims get to the best possible attorneys, to ensure they get the best possible compensation for their ordeal, and we will do our absolute best to make certain all of the attorneys are women.” http://USDrugWatchdog.Com

U.S. District Court for the Southern District of West Virginia Multidistrict litigation (MDL) consolidates all similar cases into one courtroom and will include the Defendants:

C.R. Bard, Inc., (MDL No. 2187);

American Medical Systems Inc., MDL No. 2325);

Boston Scientific Corp., (MDL No. 2326); and Johnson & Johnson’s Ethicon, Inc. (MDL No. 2327)

For the original version on PRWeb visit: http://www.prweb.com/releases/prweb2012/10/prweb9976688.htm


Source: prweb



comments powered by Disqus